Superficial spreading melanoma stage III – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:09:37 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Superficial spreading melanoma stage III – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effects of ATL001 and Nivolumab for Adults with Metastatic or Recurrent Melanoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-atl001-and-nivolumab-for-adults-with-metastatic-or-recurrent-melanoma/ Wed, 29 Apr 2026 14:29:42 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-atl001-and-nivolumab-for-adults-with-metastatic-or-recurrent-melanoma/ This clinical trial is focused on studying a type of skin cancer called metastatic or recurrent melanoma. The study is testing a new treatment approach using a personalized therapy called ATL001, which is a type of cell therapy. This therapy involves using the patient’s own immune cells, specifically T cells, which are modified to better recognize and attack cancer cells. The study also involves a medication called nivolumab, which is known by the brand name OPDIVO. Nivolumab is a type of drug that helps the immune system fight cancer by blocking a protein that stops the immune system from attacking cancer cells.

The purpose of this study is to evaluate the safety and how well the treatment works when using ATL001 alone and in combination with nivolumab. Participants in the study will receive these treatments through an infusion, which means the medication is given directly into the bloodstream through a vein. The study will monitor participants over a period of time to observe any side effects and to see how the cancer responds to the treatment. The study aims to understand if this combination can help control the cancer and improve outcomes for patients with metastatic or recurrent melanoma.

Throughout the study, participants will have regular check-ups and tests to monitor their health and the effects of the treatment. The study will also look at changes in the size of the tumor and overall survival rates. This research is important for developing new ways to treat melanoma and potentially improve the quality of life for those affected by this disease.

]]> Study on the Effectiveness of L19IL2 and L19TNF Injections with Surgery for Patients with Stage IIIB/C Melanoma https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-l19il2-and-l19tnf-injections-with-surgery-for-patients-with-stage-iiib-c-melanoma/ Wed, 29 Apr 2026 14:23:43 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-l19il2-and-l19tnf-injections-with-surgery-for-patients-with-stage-iiib-c-melanoma/ This clinical trial is focused on studying the effects of a treatment called Daromun on patients with Stage IIIB/C melanoma, a type of skin cancer that has advanced locally but can still be surgically removed. The treatment involves two medications, Darleukin and Fibromun, which are injected directly into the tumor. These medications contain special proteins, bifikafusp alfa and onfekafusp alfa, designed to help the body fight cancer cells.

The purpose of the study is to see if using Daromun before surgery, followed by standard post-surgery treatments, can improve the time patients remain free from cancer recurrence compared to just having surgery and post-surgery treatments. Participants will be randomly assigned to receive either the Daromun treatment followed by surgery or just the surgery and post-surgery treatments. The study will monitor patients over a period to assess the effectiveness of the treatment in preventing the return of cancer.

Throughout the study, patients will receive regular injections of the medications directly into their tumors, followed by surgery to remove the cancer. After surgery, they will continue with standard treatments to help prevent the cancer from coming back. The study aims to provide valuable information on whether this new approach can offer better outcomes for patients with advanced melanoma.

]]>